elbion AG
🇩🇪Germany
Clinical Trials
5
Active:3
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
Phase 2
Terminated
- Conditions
- Overactive BladderUrinary Incontinence
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2007-08-08
- Lead Sponsor
- elbion AG
- Target Recruit Count
- 275
- Registration Number
- NCT00439192
- Locations
- 🇩🇪
Private Gynecological Practice, Alzey, Germany
🇩🇪Private Urologic Practice, Stuttgart, Germany
🇵🇱NZOZ Centrum Medyczne dr n. med. Artur Racewicz, Bialystok, Poland
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
Phase 2
Terminated
- Conditions
- Panic Disorder
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- elbion AG
- Target Recruit Count
- 24
- Registration Number
- NCT00322803
- Locations
- 🇩🇪
Charité - University Clinics Berlin, Berlin, Germany
🇩🇪Emovis, The institute of emotional health, Berlin, Germany
🇳🇱Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University, Maastricht, Netherlands
News
No news found